NCT05146336 CytOSorb TreatMent Of Critically Ill PatientS Registry
| NCT ID | NCT05146336 |
| Status | Recruiting |
| Phase | — |
| Sponsor | CytoSorbents, Inc |
| Condition | Septic Shock |
| Study Type | OBSERVATIONAL |
| Enrollment | 3,000 participants |
| Start Date | 2022-06-22 |
| Primary Completion | 2032-06 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 3,000 participants in total. It began in 2022-06-22 with a primary completion date of 2032-06.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Registry intended to provide a data repository and reporting infrastructure for the surveillance of CytoSorb device use in real-world critical care settings, and to serve as an objective, comprehensive, and scientifically-based resource to measure and improve the quality of patient care
Eligibility Criteria
Inclusion Criteria: 1. Planned OR actual CytoSorb® 300 mL device utilization 2. Informed consent for prospective registry participation Exclusion Criteria: 1. Use of the CytoSorb® 300 mL device for antithrombotic removal only 2. Intraoperative use of CytoSorb® 300 mL device during cardiac surgery only 3. The occurrence of a complication or other medically justified circumstance that arises after written informed consent has been obtained from the patient and before or during the planned therapy and as a result of which the use of CytoSorb® 300 mL Adsorber is contraindicated or no longer appropriate.
Contact & Investigator
Ricard Ferrer Roca, MD
PRINCIPAL INVESTIGATOR
Hospital Vall d'Hebron
Frequently Asked Questions
Who can join the NCT05146336 clinical trial?
This trial is open to participants of all sexes, studying Septic Shock. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05146336 currently recruiting?
Yes, NCT05146336 is actively recruiting participants. Contact the research team at cosmos@cytosorbents.com for enrollment information.
Where is the NCT05146336 trial being conducted?
This trial is being conducted at Klagenfurt, Austria, Vienna, Austria, Aachen, Germany, Bad Oeynhausen, Germany and 11 additional locations.
Who is sponsoring the NCT05146336 clinical trial?
NCT05146336 is sponsored by CytoSorbents, Inc. The principal investigator is Ricard Ferrer Roca, MD at Hospital Vall d'Hebron. The trial plans to enroll 3,000 participants.